Immunome, Inc.

NASDAQ:IMNM

Biotechnology

Healthcare
$17.18 -2.26%

-$0.42 today

Market cap
$2.03B
Beta
2.07
P/E (TTM)
-9.1
EPS (TTM)
-$1.99
52W Low $7.96High $27.65

Volume 1.03M

Average 1.23M

IMNM Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Immunome, Inc.NASDAQ: IMNM

Operating Margin · Q3 FY2026 · quarter ended Sep 2026

Operating margin not reported for Q3 FY2026

Context

  • Operating margin widened in 1 of the last 2 fiscal years.

What to watch

Whether operating margin reaches the consensus estimate from 7 analysts of -155145.7% for the fiscal year ending Dec 2026, down from -3084.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
—— QoQ
Last fiscal yearDec 2025
-3084.8%+297.6 pp YoY
LTMSep 2026
—— YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+297.6 pp-152060.9 pp-152358.5 pp
3 years—+2963.5 pp—
5 years+3101.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-3084.8%
Year-over-year change
+297.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How IMNM compares with its peers on the latest reported figures

  • IMNM's FY2025 operating margin of -3084.8% is the 6th highest of the 7 companies compared; the peer median is -248.6%.
  • Its year-over-year change of +297.6 pp is the 2nd highest of 7, against a peer median of +15.7 pp.
IMNM Competitors Peer median
Operating Margin for IMNM and competitors
Company Period LTM level YoY 3-year change
IMCRImmunocore Holdings plcLTM Mar 2026-7.6% +6.7 pp+18.3 pp
MGNXMacroGenics, Inc.LTM Mar 2026-40.5% +24.7 pp+32.2 pp
STROSutro Biopharma, Inc.LTM Mar 2026-115.5% +261.4 pp+87.9 pp
BCYCBicycle Therapeutics plcLTM Mar 2026-381.8% +583.8 pp+465.3 pp
IMTXImmatics N.V.LTM Mar 2026-570.3% -528.3 pp-394.4 pp
IMNMImmunome, Inc.FY2025-3084.8% +297.6 pp—
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-298657.1% -288801.8 pp-14271.0 pp
SLSSELLAS Life Sciences Group, Inc.FY2025— ——
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
AVBPArriVent BioPharma, Inc. Common StockFY2025— ——
IMMXImmix Biopharma, Inc.FY2025— ——
Peer median (excluding IMNM) -248.6%+15.7 pp+25.3 pp

Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0014.02M9.04M6.94M
Cost of Revenue00002.96M
Gross Profit0014.02M9.04M3.99M
Gross Margin——100.0%100.0%57.4%
Research & Development14.11M23.27M23.09M129.54M174.33M
Selling, General & Admin11.09M13.63M19.66M32.96M43.77M
Operating Expenses25.2M36.9M123.55M314.84M218.1M
Depreciation & Amortization755K631K728K2.1M2.96M
EBITDA(23.95M)(36.26M)(28M)(151.35M)(209.44M)
EBITDA Margin——-199.7%-1674.1%-3017.4%
Operating Income(25.2M)(36.9M)(109.53M)(305.8M)(214.11M)
Operating Margin——-781.4%-3382.4%-3084.8%
Interest Income10K5K2.72M12.84M11.72M
Interest Expense10K5K000
Other Income / Expenses493K5K2.72M12.84M1.72M
Income Before Tax(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Pre-Tax Margin——-761.9%-3240.4%-3060.0%
Income Tax Expense00000
Net Income(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Net Margin——-761.9%-3240.4%-3060.0%
EPS (Basic)(2.14)(3.09)(5.38)(5.00)(2.43)
EPS (Diluted)(2.14)(3.09)(5.38)(5.00)(2.43)
Weighted Avg Shares11.54M12.13M19.84M58.64M87.35M
Weighted Avg Shares (Diluted)11.54M12.13M19.84M58.64M87.35M

Immunome, Inc.

NASDAQ:IMNM

Intrinsic Alpha fair value

Locked

Current Price

$17.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.